Full history for every metric is available with a Kvantra account
Theratechnologies Inc. (TH.TO)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 63 | 66 | 70 | 80 | 82 | 86 | 84 |
| Operating profit | $m | 8 | 7 | |||||
| Net profit | $m | -12 | -23 | -32 | -47 | -24 | -8 | -9 |
| EPS reported | $ | -0.17 | -0.19 | |||||
| Operating cashflow per share | $ | 0.05 | 0.05 | |||||
| Capex per share | $ | 0.03 | 0.03 | |||||
| FCF per share | $ | 0.02 | 0.02 | |||||
| Free cash flow | $m | 1 | -3 | |||||
| Net debt | $m | 35 | 33 | |||||
| Book value equity | $m | -25 | -28 | |||||
| Book value per share | $ | -0.51 | -0.57 | |||||
| Number of shares | m | 49.36 | 49.36 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -2.37 | -5.17 | |||||
| P/S LTM | x | 0.70 | 1.71 | |||||
| P/FCF LTM | x | 68.12 | -46.91 | |||||
| EV/EBITDA LTM | x | 14.48 | 86.47 | |||||
| EV/Sales LTM | x | 1.16 | 2.10 | |||||
| Earnings Yield LTM | % | -13.87% | -5.36% | |||||
| FCF Yield | % | 1.47% | -2.13% | |||||
| Quality | ||||||||
| ROE | % | 32.87% | 36.00% | |||||
| ROIC | % | 40.16% | 40.16% | |||||
| Operating margin | % | 9.52% | 9.52% | |||||
| Gross margin | % | 76.19% | 76.19% | |||||
| FCF/Sales | % | 1.02% | 1.02% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +5.02% | +2.19% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | +89.14% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.02 | -0.07 | |||||
| Net Debt/EBITDA | x | 5.77 | 5.77 | |||||
| EBIT/Net interest | x | 0.78 | 0.78 | |||||
| Net debt/market cap | % | 58.14% | 22.74% | |||||
| Net debt/Equity | x | -1.38 | -1.18 | |||||
| Gross debt/equity | x | -1.80 | -1.56 | |||||
Company overview
Theratechnologies Inc. is a biopharmaceutical firm dedicated to developing and bringing to market a range of treatments aimed at fulfilling critical medical needs across the US, Canada, and Europe. Its current product portfolio includes EGRIFTA and EGRIFTA SV, designed to lessen excessive abdominal fat in HIV patients suffering from lipodystrophy. Additionally, it provides Trogarzo, an ibalizumab injection, used to treat individuals with multidrug-resistant HIV-1. The company's future product pipeline features the F8 Formulation, also targeting lipodystrophy in HIV-positive individuals. Furthermore, TH1902 is undergoing Phase 1/Part A clinical trials for triple-negative breast cancer, and TH1904 is being developed for ovarian cancer. Established in 1993, the company maintains its headquarters in Montreal, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Theratechnologies Inc. (TH.TO)
Theratechnologies Inc. is a biopharmaceutical firm dedicated to developing and bringing to market a range of treatments aimed at fulfilling critical medical needs across the US, Canada, and Europe. Its current product portfolio includes EGRIFTA and EGRIFTA SV, designed to lessen excessive abdominal fat in HIV patients suffering from lipodystrophy. Additionally, it provides Trogarzo, an ibalizumab injection, used to treat individuals with multidrug-resistant HIV-1. The company's future product pipeline features the F8 Formulation, also targeting lipodystrophy in HIV-positive individuals. Furthermore, TH1902 is undergoing Phase 1/Part A clinical trials for triple-negative breast cancer, and TH1904 is being developed for ovarian cancer. Established in 1993, the company maintains its headquarters in Montreal, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free